Novo Nordisk

About

Novo Nordisk is a pharmaceutical manufacturing company that specializes in Insulin, obesity, rare diseases, and diabetes.

Bagsværd,Hovedstaden,Denmark
10001 - max
https://www.novonordisk.com

Highlights

Details

Last Funding Type: Post-IPO Equity
Last Funding Money Raised: $22M
Industries: Biotechnology,Health Care,Medical,Pharmaceutical
Founded date: Jan 1, 1923
Number Of Employee: 10001 - max
Operating Status: Active
Stock Symbol: nyse:NVO
Legal Name: Novo Nordisk A/S

Novo Nordisk is a pharmaceutical manufacturing company that specializes in Insulin, obesity, rare diseases, and diabetes. Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

2

$22M

Novo Nordisk has raised a total of $22M in funding over 2 rounds. Their latest funding was raised on Dec 5, 2018 from a Post-IPO Equity round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Dec 5, 2018	Post-IPO Equity	$22M	—	—	—	Detail
May 8, 1981	IPO	—	—	—	—	Detail

Investments

Number of Investments

Number of Lead Investments

11

2

Novo Nordisk has made 11 investments. Their most recent investment was on Sep 29, 2022, when Ventus Therapeutics raised $70M.

Date Company Name	Round	Money Raised	Industry	Lead Investor
Sep 29, 2022 Ventus Therapeutics	Corporate Round	$70M	Biotechnology	Yes
Feb 17, 2022 Beta Bionics	Series C	$57M	Biotechnology	—
Mar 16, 2021 Glooko	Series D	$30M	Diabetes	—
Sep 24, 2020 Sundew	Seed	€1.51M	Agriculture	—
Jan 5, 2016 IO Biotech	Series A	€11M	Biotechnology	—

Employee Profiles

Number of Employee Profiles

47

Novo Nordisk has 47 current employee profiles, including Employee Jesper HØiland

Jesper HØiland

Employee

Christina Rottbøll Andersen

Executive

Maziar Mike Doustdar

Executive

Helene Faustrup Kildegaard

Employee

Janos Kodra

Executive

Exits

Novo Nordisk has had 4 exits. Novo Nordisk most notable exits include IO Biotech , Innate Pharma

Date	Company Name	Exit Type	Industry
Nov 5, 2021	IO Biotech	IPO	Biotechnology	Detail
Oct 17, 2019	Innate Pharma	IPO	Biopharma	Detail
Sep 12, 2014	Affimed	IPO	Biotechnology	Detail
Dec 3, 2013	Xencor	IPO	Biotechnology	Detail

Acquisition

Novo Nordisk has acquired 10 organizations. Their most recent acquisition was ZymoGenetics on Jan 1, 1988. They acquired ZymoGenetics for 0.

Date Company Name	Industry	Acquisition Type	Price
Jan 1, 1988 ZymoGenetics	Therapeutics	acquisition	—	Detail
Oct 1, 2003 Aldaph SpA	Manufacturing	acquisition	—	Detail
May 21, 2013 Xellia Pharmaceuticals	Biotechnology	—	$ 700M	Detail
Aug 27, 2015 Calibrium	Biotechnology	acquisition	—	Detail
Aug 27, 2015 MB2	Health Care	acquisition	—	Detail